Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Delord JP, et al. Among authors: pages c. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. Target Oncol. 2021. PMID: 33170484 Clinical Trial.
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP. Lebbé C, et al. Among authors: pages c. Target Oncol. 2021 Jan;16(1):47-57. doi: 10.1007/s11523-020-00767-1. Target Oncol. 2021. PMID: 33211315 Clinical Trial.
[Treatment of patients with brain metastases from a melanoma].
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Modesto A, et al. Among authors: pages c. Cancer Radiother. 2019 Apr;23(2):147-150. doi: 10.1016/j.canrad.2018.05.006. Epub 2019 Mar 21. Cancer Radiother. 2019. PMID: 30904418 Review. French.
[Dermatologic toxicities of immune checkpoint inhibitors].
Sibaud V, Boulinguez S, Pagès C, Riffaud L, Lamant L, Chira C, Boyrie S, Vigarios E, Tournier E, Meyer N. Sibaud V, et al. Among authors: pages c. Ann Dermatol Venereol. 2018 May;145(5):313-330. doi: 10.1016/j.annder.2018.01.047. Epub 2018 Apr 18. Ann Dermatol Venereol. 2018. PMID: 29678394 Review. French.
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Jiménez M, et al. Among authors: pages c. Am J Hematol. 2023 Aug;98(8):1204-1213. doi: 10.1002/ajh.26951. Epub 2023 May 8. Am J Hematol. 2023. PMID: 37151135
Sample CME manuscript submission: Response to the article by Pham et al entitled "Review BRAF inhibition and the spectrum of granulomatous reactions".
Marcaillou M, Dion J, Baroudjian B, Ezrine E, Carrera C, Anderle A, Apalla Z, Freites-Martinez A, Pages C, Lebbe C, Meyer N, Sibaud V, Comont T. Marcaillou M, et al. Among authors: pages c. J Am Acad Dermatol. 2022 Aug;87(2):e85-e88. doi: 10.1016/j.jaad.2022.04.053. Epub 2022 May 5. J Am Acad Dermatol. 2022. PMID: 35526651 No abstract available.
166 results